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Abstract: 
Rotenone-mediated mitochondrial complex I inhibition was used to model Parkinson‘s disease-like syndrome in Lewis rats. 
Tyrosine hydroxylase immunolabeling demonstrated a decrease in the number of dopaminergic neurons as well as aberrant 
morphology in surviving neurons. Administration of carnitinoid compounds (synthetic lipoylcarnitine or butyrylcarnitine 
compounds) reduced dopaminergic neuronal cell loss with characteristic morphology observed in surviving neurons. In a rat 
primordial hippocampal cell line (H19-7/IGF-IR), rotenone treatment resulted in increased ROS and reduced cellular ATP, while 
co-treatment with lipoylcarnitine maintained ROS and ATP at control levels. These results illustrate the therapeutic potential of 
small-molecule carnitinoids in treating neurodegenerative diseases associated with mitochondrial dysfunction. 
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INTRODUCTION 
of cellular metabolicsourceprimaryMitochondria are the
energy in eukaryotes and are essential for normal cellular 
function, proliferation and survival. Mitochondrial dysfunction 
can have severe negative ramifications on cellular function, 
particularly in tissues with elevated energy requirements. 
Mitochondria have been implicated in a number of human 
neurodegenerative diseases affecting both the old and the 
young [1]. As the entry point of high-energy electrons 
affording maximal proton-motive force, mitochondrial 
complex I (CI; NADH-CoQ reductase) of the mitochondrial 
electron transport chain is a critical initiator of mitochondrial 
energy transduction. Functional disruption of CI can drastically 
reduce neuronal energy production while increasing generation 
of harmful reactive oxygen species (ROS). If the resulting 
oxidative damage is not somehow alleviated, intrinsic pro-
apoptotic pathways may be activated [2], setting the stage for a 
variety of human neuropathological conditions [3]. In animal 
models, experimentally-induced CI inhibition results in 
aberrant neuronal bioenergetics that can manifest as abnormal 
neurobehavioral phenotypes. This fundamental etiology is 
representative of many progressive neurodegenerative diseases, 
including mitochondrial encephalomyopathy; lactic acidosis, 
and stroke-like episodes (MELAS); Leigh‘s syndrome; 
Alzheimer‘s disease; and Parkinson‘s disease (PD) [4,5]. While 
the prevalence of MELAS and Leigh‘s syndrome is low, 
Alzheimer‘s disease affects more than five million people in the 
United States alone [6], while PD affects at least one million 
people in the United States and is projected to affect over nine 
million people worldwide by 2030 [7].   
Dysfunctional mitochondria normally degraded byare
whichautophagy inofspecialized formamitophagy,
mitochondria are sequestered into autophagosomes that 
subsequently fuse with lysosomes for enzymatic degradation of 
their contents [8]. Mitophagy is critical for maintaining 
mitochondrial quality, reducing the generation of ROS from 
damaged mitochondria, and preventing errant triggering of 
intrinsic apoptotic pathways [9]. Reports suggest that, while 
moderate oxidative stress and mitochondrial damage might 
compromise some autophagic processes [10], mild oxidative 
stress appears to promote mitophagy [11]. In some progressive 
neurodegenerative diseases, continued production of ROS by 
dysfunctional mitochondria is believed to overwhelm the 
capacity for clearance by mitophagy. The overproduction of 
ROS can contribute to cellular damage and triggering of 
apoptosis, or, in extreme situations, uncontrolled cell death 
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(necrosis). Mitochondrial-targeted antioxidants have the 
potential to mitigate ROS generation by CI and thereby reduce 
mitochondrial injury and its consequences.  
The pesticide rotenone is a potent and irreversible inhibitor of 
mitochondrial CI [12]. Rotenone exposure was found to reduce 
ATP production and increase accumulation of reactive oxygen 
and nitrogen species, including superoxide and peroxynitrites. 
These accumulations result in free radical-induced damage to 
mitochondrial DNA (mtDNA) and mitochondrial proteins and 
membranes [13] along with nuclear DNA and other cellular 
components. Impaired mitochondrial function and eventual 
death of dopaminergic (DA) neurons of the ventral SNpc 
region of the midbrain are associated with PD [14]. DA 
neurons are thought to be particularly vulnerable to oxidative 
stress due to their high basal rate of oxygen metabolism, high 
iron content, and insufficient cellular antioxidants [15]. 
Demonstrable neurodegeneration of SNpc neurons in certain 
rodent models of PD makes these models useful in evaluating 
potential therapeutic compounds—not only for PD, but for a 
variety of human diseases in which mitochondrial dysfunction 
contributes to disease pathology. In general, animal models of 
PD may be regarded as representative of CI-associated energy 
metabolism defects and associated neuropathology [16]. As 
such, the rat-rotenone model is useful in evaluating potential 
therapies for mitochondrial disease.  
PMX-500FI (lipoyl-L-carnitine methyl ester iodide) is a novel, 
synthetic small-molecule compound that contains both L-
carnitine (LC) and -lipoic acid (ALA) moieties. In normal 
metabolism, cells utilize LC to shuttle long-chain fatty acids 
into mitochondria where they are burned for energy. LC also 
displays antioxidant activity. ALA is an essential cofactor in 
aerobic metabolism and one of the most potent antioxidants in 
nature. Although ALA is present in a variety of foods, its 
bioavailability from dietary intake is limited. Both ALA and a 
therapeutic combination of LC and ALA were shown to have 
beneficial effects in rodent models of PD [17,18]. ALA and LC 
are also common components in various formulations of the 
―Mito Cocktail‖, a patient-specific combination of vitamins, 
co-factors, antioxidants and other supplements intended to 
alleviate some of the symptoms of mitochondrial disease.  
PMX-550DBr (butyryl-L-carnitine ethyl ester bromide) was 
engineered to leverage the mitochondrial targeting ability of 
carnitine with the histone deacetylase activity of butyrate [19]. 
Butyric acid was shown to stimulate neuroprotective cellular 
pathways in response to oxidative damage [20,21] and has 
shown promise in treating a variety of neuropathologies 
including certain types of cancer [22].  
Previously, our group demonstrated that PMX-500FI 
protected against rotenone-induced impairment of neuronal 
function and bioenergetics in the mouse hippocampus [23]. 
Oxidative stress and neuromotor deficits were also reduced by 
PMX-500FI in rotenone-treated mice [24,25]. The present 
study evaluated the neuroprotective potential of PMX-500FI 
and PMX-550DBr in rotenone-treated Lewis rats, a common 
animal model of mitochondrial dysfunction-induced PD.  
We modified the protocol of Cannon et al. [26] to produce a 
PD phenotype in Lewis rats via rotenone administration and 
utilized this model for in vivo testing of synthetic small-
molecule carnitinoid compounds that were developed 
specifically for restoring normal mitochondrial function in 
mitochondrial disease and other human pathologies associated 
with mitochondrial dysfunction [21,27]. These compounds 
were designed to be actively taken up by mitochondria and to 
neutralize harmful oxidants, while potentially modulating the 
expression of genes involved in recycling of defective 
mitochondria. Our experiments demonstrated that both PMX-
500FI and PMX-550DBr co-administration in rotenone-treated 
rats had a neuroprotective effect on SNpc DA neurons; 
however, there was no discernable neuromotor/behavioral 
improvement. In addition, we include further evidence for a 
protective effect of PMX-500FI on mitochondrial 
bioenergetics and ROS clearance in rotenone-induced 
mitochondrial dysfunction in the rat H19-7/IGF-IR primordial 
hippocampal cell line (―H19-7 cells‖).  
RESULTS 
Neither PMX Compound Improved Performance in 
Neuromotor Testing in Rotenone-Treated Rats.  
In our modeling of mitochondrial dysfunction in rats, daily 
injections of rotenone for 14 days produced a characteristic 
phenotype in Lewis rats, and resulted in degeneration of TH-ir 
DA neurons of the SNpc (Figure 1b). A variety of tests were 
performed to assess the CI inhibition-mediated phenotype in 
this model and to determine if PMX co-treatment had a 
beneficial effect on various neuromotor parameters. The 
rotenone-induced phenotype included bradykinesia, hind limb 
rigidity and weight loss, along with reduced performance in 
balance beam, rotarod, and most facets of the open field test 
(p<0.05). In initial trials, testing two days after treatment 
showed no beneficial effect for either PMX-500FI or PMX-
550DBr, prompting modification of the protocol to introduce 
a one-week recovery period so that the animals could 
recuperate from possible systemic effects of acute rotenone 
toxicity. Even with an extended (one-week) recovery period, 
no performance differences were detectable in any neuromotor 
or behavioral tests in PMX-treated rats. Co-administration of 
rotenone treated rats with either PMX-550DBr or ALA + LC 
had a positive effect on weight gain during the recovery period 
(p<0.05). 
PMX-500FI and PMX-550DBr Protected DA Neurons in 
Rotenone-Treated Rats.  
Following neuromotor/behavioral testing, post-mortem 
samples of brain were collected for immunohistochemical 
analyses [28]. DA neurons in sections of midbrain were labeled 
with an antibody to tyrosine hydroxylase, the rate-limiting 
enzyme involved in dopamine synthesis. Neuroprotection was 
visually discernable in midbrain sections from rats co-treated 
with PMX compounds (Figure 1). Quantitative analysis 
confirmed that PMX-500FI and PMX-550DBr co-treatment 
protected DA neurons from rotenone-induced degeneration, 
and that PMX-500FI, PMX-550DBr and ALA+LC co-
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treatments also resulted in fewer surviving TH-ir cells 
displaying abnormal morphology (Figure 2). 
Rotenone-Induced Intracellular ROS Generation in H19-7 
Cells was Reduced by PMX-500FI 
Dysfunctional mitochondria, such as those with diminished CI 
function, are major sources of cellular ROS generation. In pilot 
experiments, different concentrations and durations of 
rotenone exposure were tested for ROS production. Initially, 
we determined that 10 µM rotenone induced high levels of 
ROS generation, without causing cell loss (p<0.05), in H19-7 
primordial hippocampal neurons. Neurons were subsequently 
exposed to 10 µM rotenone for different durations; results 
from these experiments showed that 4 h exposure was optimal 
for inducing ROS production (Figure 3A; n=6, p<0.01), 
whereas longer exposures resulted in excessive cell death (data 
not shown). We then assessed the effectiveness of PMX-500FI 
in reducing ROS using 0.2, 0.5 or 1.0 mM PMX-500FI. After 
3.5 h of exposure to rotenone and PMX-500FI, 2‘,7‘–
dichlorofluorescein diacetate (DCFDA, a fluorogenic dye used 
to measure hydroxyl, peroxyl and other ROS) was added to a 
final concentration of 20 µM and incubated for an additional 
30 min. Results illustrated that rotenone exposure increased 
ROS generation (514  11.1 arbitrary units (AU) after rotenone 
exposure and 415  19.0 AU in controls [mean  SEM]) and 
PMX-500FI reduced ROS levels (347  29.7, 334  7.7 and 
297  6.2 AUs for PMX-500FI doses 0.2, 0.5, and 1 mM, 
respectively) generated by 4 h rotenone exposure (Figure 3B; 
n=6, p<0.001).  
Reduction of ATP Levels by Rotenone in H19-7 Cells was 
Reversed by PMX-500FI 
Oxidative stress from excessive ROS production results in 
mitochondrial damage and reduction in mitochondrial 
abundance. Since PMX-500FI reduced intracellular ROS, we 
tested the ability of PMX-500FI to preserve mitochondrial 
energy production in H19-7 cells. Results of these experiments 
illustrate that rotenone reduced ATP production (476  6.2 nM 
in rotenone treated cells when compared to 520  19.5 nM in 
controls) and PMX-500FI prevented the reduction in ATP 
(529  9.1 and 519  5.5 nM for 0.5 mM and 1 mM PMX-
500FI doses, respectively) in rotenone-exposed H19-7 cells 
 
 
 
 
 
Fig. (1).Immunohistochemistry of rat brain SNpc labeled with a primary antibody specific for tyrosine hydroxylase. Control 
untreated (A), Rotenone treated (B), Rotenone co-treated with ALA+LC (C), Rotenone co-treated with PMX-500FI (D), Rotenone 
co-treated with PMX-550DBr (E).  
 
Fig. (2).Quantitative immunohistochemical analysis of TH-ir neurons in SNpc of rat brain striatum in rats treated with rotenone 
only and in rotenone-treated rats that were co-treated with the lipoylcarnitine PMX-500FI or the butyrylcarnitine PMX-550DBr. 
TH-ir (DA neurons) cell counts and necrotic (amorphic) TH-ir cell counts were similar in samples from control rats and rotenone-
treated rats that were co-treated with either PMX-500FI or PMX-550DBr, while rotenone-only treated rats showed decreased TH-
ir cell counts and increased amorphic TH-ir cell counts. TH-ir cell counts from rotenone-treated rats that were co-treated with a 
combination of ALA and LC showed no improvement compared to rotenone only. [*p< 0.05; control untreated, n= 5; rotenone 
only, n=6; rotenone + co-treatments (ALA + LC, PMX-500FI, or PMX-550BDr), n=5]. 
* 
A B C D E 
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(Figure 3C; n=4, p<0.01). Hence, PMX-500FI mitigated ROS 
production and improved bioenergetics in cells with rotenone-
induced impairment of CI function. 
DISCUSSION 
The central nervous system (CNS) is highly susceptible to 
oxidative injury due to its high oxygen consumption combined 
with a relatively high basal production of ROS and the loss of 
regenerative capacity of the majority of neurons after 
differentiation. This implies that an effective first line of 
therapeutic defense against oxidative injury could be the use of 
potent exogenous antioxidant compounds that supplement the 
actions of endogenous antioxidants, increasing the net 
antioxidant defense capacity. Unfortunately, synthetic 
antioxidants have generally proven severely limited in their 
ability to provide neuroprotection, necessitating more effective 
alternatives [29]. We recently demonstrated that a novel 
lipoylcarnitine antioxidant compound, PMX-500FI, protected 
mouse hippocampi from rotenone-induced deficits in synaptic 
plasticity and cellular stress signaling [25]. Here we 
demonstrate that PMX-500FI reduced ROS and improved 
energy (ATP) production in a neuronal cell line challenged with 
rotenone. 
Although the mechanisms of CI inhibition by rotenone have 
not been fully elucidated, there is an established correlation 
between CI inhibition and apoptosis, triggered by excess 
generation of ROS [30]. In non-proliferating mature neurons, 
mitochondrial dysfunction and apoptosis are associated with 
increased ROS production [31]. We found a substantial 
increase in ROS production with concentrations of rotenone 
higher than 0.1 M, in agreement with reports that showed a 
similar increase in ROS in HL-60 cells [30] and HeLa cells [32]. 
Interestingly human neural stem cells required higher 
concentrations of rotenone for ROS production [33]. Results 
of this study show a relatively high dose but short duration (4 
h) of rotenone exposure produced high levels of ROS. 
However, a longer (12 h) exposure time resulted in markedly 
reduced ROS levels likely due to rapid onset of death and 
clearance of cells. Results of this and other studies confirm that 
CI inhibition by rotenone results in enhanced generation of 
ROS in neurons. A major protective mechanism of natural 
cellular antioxidants is to scavenge ROS and thereby reduce 
cellular injury. Several natural and synthetic compounds were 
reported to effectively scavenge ROS resulting in 
neuroprotection [34,35]. Results of this study clearly 
demonstrate that PMX-500FI treatment reduced ROS levels, 
indicating a direct ROS scavenging capability and/or 
prevention of ROS generation by this antioxidant. 
There is an intricate relationship among mitochondrial 
dysfunction, ROS production and decreased ATP production. 
Increased cellular ROS production is a potent factor that can 
reduce mitochondrial ATP output [36] and even a modest 30% 
decrease in ATP is capable of precipitating apoptosis [37]. 
Results of this study also show that rotenone-induced ROS 
generation was associated with reduced ATP levels. Some 
antioxidants have been shown to preserve ATP levels in cells 
and tissues under oxidative stress [38]; and, indeed, results of 
this study indicate that PMX-500FI decreased ROS levels while 
also preventing reduced generation of ATP. 
Various genetic approaches have been used to model human 
neurodegenerative diseases in rodents, from fusion of 
cytoplasts with ES cells (resulting in ―cybrid‖ cells [39]) to 
produce transmitochondrial mice harboring mtDNA mutations 
[39,40] to conventional transgenic models of PD [41], 
Alzheimer‘s [42], Huntington‘s [43] and other CNS 
neurodegenerative diseases. Although the technology for 
manipulating nuclear genes in a directed fashion is well 
established and straightforward (particularly for mice), 
production of animal models that faithfully mimic human 
diseases associated with mtDNA mutations has proven elusive 
[40]. However, considering the fact that seven of the thirteen 
polypeptides encoded by mtDNA are CI subunits, it would 
logically follow that CI function is particularly vulnerable to 
random mutations of mtDNA. Therefore, specific inhibition of 
CI (e.g., with chemicals such as rotenone) might prove useful 
 
Fig. (3). ROS production and ATP content in H19-7 rat primordial hippocampal neurons after selective CI inhibition by rotenone 
and protective effects of PMX-500FI. (A) Four hour duration of rotenone (10 µM) exposure increased ROS (n=6; **p<0.01). (B) 
Co-exposure of PMX-500FI with rotenone (4 h) resulted in reduced ROS (n=6; **p<0.01, ***p<0.001). (C) Rotenone exposure 
(10 µM, 4 h) reduced cellular ATP levels. Treatment with PMX-500FI resulted in preservation of ATP levels (n=4; **p<0.01).  
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for modelling some of the general phenotypic effects of 
mtDNA mutation, including neurodegenerative diseases in 
which a decline in CI function is often associated with CNS 
pathology.  
Rotenone neurotoxicity in rodent models of PD is believed to 
be mediated principally by CI dysfunction and the resulting 
concomitant production of excess ROS and oxidative damage. 
While rotenone is clearly a specific and irreversible inhibitor of 
CI, it also displays microtubule depolymerization activity, 
which should not be discounted in terms of its potential to 
affect neuronal function [44]. In addition, there is evidence that 
at least part of the rotenone-induced phenotype in rodent 
models is due to general systemic toxicity and bears no 
relevance to PD-like symptoms [45]. Although rodent models 
of PD are useful, the complexity of environmental and 
multigenic interactions that come into play in spontaneous 
idiopathic cases of PD should serve to dissuade one from 
making overarching inferences regarding the utility of any 
particular animal or cellular model for the study of this disease 
[46]. 
In this study, we found that two synthetic carnitinoid 
compounds, a lipoylcarnitine (PMX-500FI) and a 
butyrylcarnitine (PMX-550DBr), conferred neuroprotection 
from rotenone-induced depletion of TH-ir neurons in the 
SNpc of Lewis rats, and that surviving TH-ir neurons appeared 
more normal by morphometric analysis. The mechanisms of 
neuroprotection in these models likely relate in large part to 
improved mitochondrial function, given that rotenone acts 
primarily on CI function. However, epigenetic histone 
deacetylase inhibitory (HDACi) activity of PMX-500FI and 
PMX-550DBr [47], might also provide neuroprotective effects 
via induction of antioxidant response elements which 
upregulate transcription of cytoprotective genes, including 
components of the cellular antioxidant system that functions to 
balance high ROS levels. 
Rotenone-induced CI inhibition in Lewis rats is a well-
established animal model of PD [12,26]; however, most studies 
to date administered rotenone over longer periods (typically 28 
days) and used very narrowly defined, single-method measures 
for assessing neuromotor impairment. In this study, we sought 
to develop a treatment regimen that produced a less 
debilitating phenotype that would allow for more subtle and 
more diverse assessment of neuromotor function, and would 
thus lend itself to more informative preclinical evaluation of 
potential therapeutic compounds, such as the PMX 
compounds investigated in this study. With our modified 
protocol using Lewis rats, neuromotor testing showed a clear 
rotenone-induced deficit; however, although PMX-treated rats 
subjectively appeared to recover somewhat from rotenone-
induced bradykinesia and hind limb rigidity, improved 
performance in neuromotor testing was not documented.  
In this study, a clear neuroprotective effect of PMX-500FI or 
PMX-550DBr co-treatment by quantitative analysis of tyrosine 
hydroxylase immunohistochemical labeling of DA neurons in 
the SNpc was demonstrated. As it was our aim to correlate 
neuromotor performance gains with neuroprotection of SNpc 
DA neurons, we modified the protocol to include a longer 
(one-week) recovery period after rotenone/PMX treatments 
(prior to neuromotor testing). Although we found a beneficial 
effect on recovery from rotenone-induced weight loss for 
PMX-550DBr with the one-week recovery period, no 
improvements in neuromotor or behavioral performance were 
noted. 
Previous studies from our laboratory on rotenone-induced CI 
dysfunction in normal mice showed beneficial effects from 
PMX-500FI in a variety of neuronal functions, including 
protection against ROS production in brain and neuromotor 
decline [25], increased long term potentiation in hippocampal 
neurons and stabilization of synaptic physiology and 
transmission [23]. PMX-500FI co-treatment revealed a 
beneficial effect on rotenone-mediated activation of oxidative 
stress-related proteins SAPK/JNK and pERK1/2. PMX-
500FI showed presumptive antiapoptotic activity via 
phosphorylation of BAD (pBAD) and decreased BAX 
translocation to mitochondria [23]. PMX-500FI and PMX-
550DBr also demonstrated HDACi activity via 
hyperacetylation of histone H3 in assays using the H19-7 cell 
line [47].  
Impaired mitochondrial function is associated with most 
progressive neurodegenerative diseases as well as with the 
normal aging process itself [48], and is central to the 
pathological changes in mitochondrial disease proper. 
Increased production of ROS along with insufficient ATP 
production by dysfunctional mitochondria could potentially 
overwhelm the cellular capacity for clearance by mitophagy and 
accelerate oxidative damage and triggering of intrinsic 
apoptotic pathways. Mitochondrial-targeted antioxidants that 
also possess HDACi activity have the potential to mitigate 
ROS generation and potentially stimulate recycling of 
dysfunctional mitochondria, thereby reducing mitochondrial 
injury and its consequences in these devastating diseases. As 
such, they represent a class of compounds with possible 
clinical relevance that warrant continued study. 
METHODS 
Reagents 
Rotenone used in cell culture and rat experiments was obtained 
from MP Biomedicals (Solon, OH, USA). Miglyol 812N (Sasol 
Germany GmbH), used as a vehicle for rotenone injection [26], 
became unavailable early on in the study and was replaced with 
a similar product, Neobee M-5 (a caprylic/capric triglyceride; 
Spectrum Chemical Mfg., New Brunswick, NJ, USA). PMX-
500FI, PMX-550DBr, ALA and LC were supplied by 
PhenoMatriX, Inc. (Natick, MA, USA). Each was dissolved in 
dimethyl sulfoxide (DMSO) at 40-80 mg/ml, except for LC, 
which was dissolved in PBS at 40 mg/ml. Rotenone was 
dissolved in DMSO at 5 mg/ml and was prepared fresh twice a 
week during the course of the experiments. All solutions were 
sterile filtered prior to use. Treatment compounds were vortex-
mixed with Neobee M-5 vehicle immediately prior to 
intraperitoneal (IP) injection. All other reagents were of the 
highest grade commercially available from Sigma-Aldrich (St. 
Louis, MO, USA) or Cayman Chemical (Ann Arbor, MI, 
USA). 
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Cell Culture, Chemicals and Treatment 
Rat H19-7/IGF-IR primordial hippocampal cells (H19-7 cells; 
CRL-2526, ATCC) were seeded onto sterile 10 cm culture 
dishes and 6- or 24-well culture plates pre-coated with poly-L-
lysine (Gibco/ThermoFisher, Waltham, MA, USA) and were 
allowed to proliferate at 34 °C in 10% CO2 in air until they 
reached ~80% confluence. The culture medium contained 
high-glucose Dulbecco‘s modified Eagle‘s medium 
supplemented with 10% Fetal Clone IIITM (Gibco/ 
ThermoFisher), 50  U/ml penicillin, 50  U/ml streptomycin, 
1X GlutaMAXTM (Gibco/ThermoFisher), 1  mM sodium 
pyruvate and 200  μg/ml G418 sulfate (Mediatech/Corning, 
Tewksbury, MA, USA). Differentiation was induced by 
increasing incubation temperature to 39 °C and including N2 
supplement (Gibco) and basic fibroblast growth factor (10 
ng/ml; Invitrogen/Thermo-Fisher) to the culture medium. 
Rotenone and PMX-500FI were dissolved in DMSO and 
diluted in complete medium. DMSO final concentration was 
kept at or below 0.1% to avoid cell toxicity issues.  
Intracellular ROS and ATP Content 
H19-7 cells were cultured in 24-well plates until reaching 80% 
confluence and were then differentiated as described above. 
Generation of intracellular ROS in response to different doses 
of rotenone, exposure time and co-treatment with PMX-500FI 
was measured by loading culture medium with 20 µM 2‘,7‘-
dichlorofluorescin diacetate (DCFDA) for 30 min. Cellular 
ATP content among different groups was determined using an 
ENLITEN® ATP Assay System Bioluminescence Detection 
Kit (Promega, Madison, WI, USA) according to the 
manufacturer‘s instructions. Fluorescence (at Ex485nm/ 
Em535nm) and luminescence were measured using a Tecan 
Infinite M200 multi-function microplate reader (Tecan, 
Männedorf, Switzerland) equipped with Magellan 7.x software 
(Tecan).  
Animals 
Male Lewis rats (9-10 weeks old, 200-250 g) were purchased 
from Envigo (Prattville, AL, USA) and were handled 
exclusively by female technicians in all procedures [49]. 
Animals underwent a one-week acclimation period in which 
they were subjected to one-handed dorsal recumbency 
positioning by the handler. Rats were weighed daily to 
determine treatment dosages. After two weeks of daily IP 
rotenone injections (3.0 mg/kg body weight), rats displayed the 
characteristic hind limb rigidity and bradykinesia that are 
hallmarks of the rat-rotenone model [18]. Separate groups of 
rotenone-treated rats were co-treated daily with PMX 
compounds, while others were treated with a mixture of ALA 
and LC [18]. Animals received daily IP injections of 
experimental compounds (PMX or ALA+LC) in the morning 
and rotenone in the early afternoon.  
All animal procedures, including housing, neuromotor testing 
and euthanasia, conformed to Institutional Animal Care and 
Use Committee (IACUC) guidelines and the Guide for the 
Care and Use of Laboratory Animals, under Office for 
Laboratory Animal Welfare (OLAW) assurance #A3152-01. 
Specifically, all animal procedures used in this study were 
reviewed and approved by the Auburn University IACUC 
(reference protocol number 2015-2646). 
Immunohistochemistry 
Immunolabeling of brain slices [28] was performed on rats 
from experiments in which neuromotor testing had 
commenced two days post-treatment (i.e., euthanasia at four 
days post-treatment). Animals were anesthetized with a 
combination of ketamine (100 mg/kg) and xylazine (20 mg/kg) 
and fixation was accomplished by transcardial perfusion with 
4% paraformaldehyde in phosphate buffered saline (PBS), pH 
7.2. Whole fixed brains were removed and stored in fixative at 
4 C for two days, followed by 30% sucrose with daily changes 
for 3-4 days before sectioning and immunohistochemical 
analysis. Coronal brain slices (30µm thick) were prepared using 
a cryostat. Immunohistochemical analysis was performed on 
every fourth free-floating section. All procedures prior to 
antibody incubation were carried out at room temperature. 
Sections were washed in PBS with 0.1% Triton X-100 (PBST) 
for several hours to remove cryoprotectant, and were 
incubated in PBST containing 3% normal goat serum (ICN 
Biochemical, Costa Mesa, CA, USA) for 1 h. Sections were 
then incubated in a 1:1000 dilution of a rabbit polyclonal 
antibody against tyrosine hydroxylase (AB152 from Merck 
Millipore, Billerica, MA, USA) in PBST for 2 days at 4 C. 
Following incubation, sections were washed and then placed in 
biotinylated goat anti-rabbit IgG (Jackson Immunoresearch, 
West Grove, PA, USA), 1:000 dilution in PBST for 1 h. The 
sections were washed in PBST and then incubated in PBST 
containing ABC-elite (1:1000; Vector Laboratories, 
Burlingame, CA, USA) for 1 h. After rinsing in PBS, sections 
were incubated in 0.05% 3,3'-Diaminobenzidine (DAB) and 
0.015% H2O2 in PBS for 10 min. Sections were rinsed in PBS, 
mounted on positively charged glass slides and allowed to dry. 
Slides were dehydrated in ethanol and cover-slipped with 
Permount (Electron Microscopy Sciences, Hatfield, PA, USA). 
Controls included omission of the primary antibody from the 
immunohistochemical analysis protocol, the absence of which 
completely eliminated DAB staining for the antigen. Tyrosine 
hydroxylase immunoreactive (TH-ir) cells were counted 
unilaterally in four consecutive sections of the dorsal tier of 
SNpc (SNpc-A9d) by a blinded observer. Imaging was 
performed using a Nikon Eclipse E800M microscope and 
whole-section mosaics of high-magnification images were 
assembled using Nikon Elements 5.1 software, which was also 
used for quantitative analysis of TH-ir cells. 
Neuromotor Analyses 
At the conclusion of the two-week treatment period, rats were 
subjected to neuromotor testing after either a two-day or a 
one-week recovery. Rat neuromotor and behavioral tests 
included rotarod, open field test and balance beam, and were 
conducted over a two day period.  
Rotarod 
Motor coordination and balance in rats were tested using a 
rotarod (Rotamex, Columbus Instruments, Columbus, OH, 
USA). Prior to performance testing, rats were trained to 
balance on the rotarod. Two variations of training were used, 
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each with different timing of performance testing. In the first 
variation, rats were introduced to the rotarod apparatus one 
day after experimental treatments with rotenone and PMX 
compounds ended, and training lasted for just one day, with a 
series of short training sessions throughout the day.  
In performance trials, the rotarod was programmed to begin at 
4 rpm and increase by 1 rpm every 8 sec until a maximum 
speed of 40 rpm was reached. Latency to fall (measured as time 
passed since rod rotation began) was recorded by the rotarod 
apparatus. Three trials were run with the results averaged and 
rats were given a 30 min rest period between trials. 
Open Field Test 
The open field test is a quantitative measure of general 
locomotor activity and exploratory behavior. Rats were placed 
in the center of the floor of an empty clear acrylic box (100cm 
x 100cm x 100cm) and allowed to explore for 10 min. Sessions 
were video recorded by a centrally-aligned overhead camera, 
and animal movement was tracked using SMART software 
(v3.0; Panlab, Harvard Apparatus, Holliston, MA, USA). The 
full dataset for each rodent was analyzed using the SMART 
software package. Among the variables analyzed were total 
distance traveled, percent time spent resting versus moving, 
and mean speed. Following completion of the software 
analysis, video footage was reviewed by a human observer and 
scored for the number of rears.  
Balance Beam 
To test balance and coordination, rats were trained to cross a 
wooden balance beam elevated approximately 3 feet off the 
floor. The starting end of the beam apparatus consisted of an 
open platform with a light source directed towards the beam to 
prompt the rodent to traverse the beam into the darkened 
―safe‖ box at the beam terminus. Wooden beams for these 
experiments were 1.5‖ square and round dowels. Initial training 
of animals was performed using the square beam, placing the 
rodent on the center of the beam with its head facing the box. 
Once inside the box, the animals were allowed 30 sec of rest 
and then repositioned at the start of the beam. Following 
training, each animal was placed at the start of the balance 
beam a total of 6 times and allowed to cross (3 crossings on the 
square beam followed by 3 crossings on the round beam after a 
30 min break). Each trial was video recorded, with the field of 
view directly down the beam lengthwise, which allowed for a 
clear view of hind foot faults. Videos were later manually 
scored for foot faults/slips (the number of times the animal‘s 
foot slipped off the balance beam). After tallying of all foot 
faults was completed, averages were compared for square 
beam, round beam, and total foot faults. 
STATISTICAL ANALYSIS 
Statistical analyses were performed using R-studio software 
with the ‗asbio‘ package. Data were analyzed using one-way 
ANOVA with Tukey HSD post hoc test. Statistical significance 
was accepted at p<0.05. 
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